Novo Nordisk raises 2026 guidance as generic semaglutide launches abroad
Morningstar cut its fair value estimate to DKK 285 from DKK 311, citing lower gross margins and reduced CagriSema sales expectations.
TR
By Tom Reyes · Markets Editor
Aug 6 03:00 ETSource: morningstar.com
The wire
- 01Novo Nordisk posted 6% adjusted revenue growth and 8% adjusted operating profit growth in Q2 2026 and guided 2026 sales to between flat and a 6% decline at constant currency; Copenhagen shares fell 4% on Aug. 5.
- 02Generic semaglutide is already launching in Brazil and Canada and lower-priced oral cash-pay sales are spreading, signals of price pressure relevant to pharmacies and telehealth operators sourcing semaglutide.
- 03Morningstar flags a harder second half and another CagriSema miss; the note is an equity analyst view, not company guidance on the combination's regulatory path.
From the source
Read at morningstar.comNovo Nordisk Earnings: Price Pressure Growing with Oral Cash Pay Success and Another Cagrisema Miss
Novo Nordisk NVO saw 6% adjusted revenue growth and 8% adjusted operating profit growth in the second quarter. Management raised its 2026 guidance at constant exchange rates for sales and operating profit to between flat and a 6% decline. Copenhagen-listed shares fell 4% on Aug. 5.
